Literature DB >> 15987754

Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters.

Jaspreet Singh Jaggi1, Surya V Seshan, Michael R McDevitt, Krista LaPerle, George Sgouros, David A Scheinberg.   

Abstract

The effect of external gamma irradiation on the kidneys is well described. However, the mechanisms of radiation nephropathy as a consequence of targeted radionuclide therapies are poorly understood. The functional and morphologic changes were studied chronologically (from 10 to 40 wk) in mouse kidneys after injection with an actinium-225 (225Ac) nanogenerator, a molecular-sized, antibody-targeted, in vivo generator of alpha-particle-emitting elements. Renal irradiation from free, radioactive daughters of 225Ac led to time-dependent reduction in renal function manifesting as increase in blood urea nitrogen. The histopathologic changes corresponded with the decline in renal function. Glomerular, tubular, and endothelial cell nuclear pleomorphism and focal tubular cell injury, lysis, and karyorrhexis were observed as early as 10 wk. Progressive thinning of the cortex as a result of widespread tubulolysis, collapsed tubules, glomerular crowding, decrease in glomerular cellularity, interstitial inflammation, and an elevated juxtaglomerular cell count were noted at 20 to 30 wk after treatment. By 35 to 40 wk, regeneration of simplified tubules with tubular atrophy and loss with focal, mild interstitial fibrosis had occurred. A lower juxtaglomerular cell count with focal cytoplasmic vacuolization, suggesting increased degranulation, was also observed in this period. A focal increase in tubular and interstitial cell TGF-beta1 expression starting at 20 wk, peaking at 25 wk, and later declining in intensity with mild increase in the extracellular matrix deposition was noticed. These findings suggest that internally delivered alpha-particle irradiation-induced loss of tubular epithelial cells triggers a chain of adaptive changes that result in progressive renal parenchymal damage accompanied by a loss of renal function. These findings are dissimilar to those seen after gamma or beta irradiation of kidneys.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987754     DOI: 10.1681/ASN.2004110945

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  31 in total

1.  Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.

Authors:  J Schwartz; J S Jaggi; J A O'Donoghue; S Ruan; M McDevitt; S M Larson; D A Scheinberg; J L Humm
Journal:  Phys Med Biol       Date:  2011-01-10       Impact factor: 3.609

2.  Branched amphiphilic peptide capsules: cellular uptake and retention of encapsulated solutes.

Authors:  Pinakin Sukthankar; L Adriana Avila; Susan K Whitaker; Takeo Iwamoto; Alfred Morgenstern; Christos Apostolidis; Ke Liu; Robert P Hanzlik; Ekaterina Dadachova; John M Tomich
Journal:  Biochim Biophys Acta       Date:  2014-02-22

3.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

Authors:  John M Pagel; Aimee L Kenoyer; Tom Bäck; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Steven I Park; Shani Frayo; Amanda Axtman; Nural Orgun; Johnnie Orozco; Jaideep Shenoi; Yukang Lin; Ajay K Gopal; Damian J Green; Frederick R Appelbaum; Oliver W Press
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

Review 4.  Actinium-225 in targeted alpha-particle therapeutic applications.

Authors:  David A Scheinberg; Michael R McDevitt
Journal:  Curr Radiopharm       Date:  2011-10

Review 5.  Modelling and dosimetry for alpha-particle therapy.

Authors:  George Sgouros; Robert F Hobbs; Hong Song
Journal:  Curr Radiopharm       Date:  2011-07

Review 6.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

7.  A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry.

Authors:  Robert F Hobbs; Hong Song; David L Huso; Margaret H Sundel; George Sgouros
Journal:  Phys Med Biol       Date:  2012-06-15       Impact factor: 3.609

8.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.

Authors:  Jaspreet Singh Jaggi; Jorge A Carrasquillo; Surya V Seshan; Pat Zanzonico; Erik Henke; Andrew Nagel; Jazmin Schwartz; Brad Beattie; Barry J Kappel; Debjit Chattopadhyay; Jing Xiao; George Sgouros; Steven M Larson; David A Scheinberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Authors:  Johnnie J Orozco; Tom Bäck; Aimee Kenoyer; Ethan R Balkin; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Shani L Frayo; Mark D Hylarides; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113

Review 10.  The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

Authors:  Evan D Read; Peter Eu; Peter J Little; Terrence J Piva
Journal:  Target Oncol       Date:  2014-05-29       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.